On January 14, the official website of the State Drug Administration of China issued the “Announcement on Canceling the Registration Certificate of Phenolphthalein Tablets and Phenolphthalein Lozenges Drugs (No. 6 of 2021)”, stating that according to the “People’s Republic of China Drug Administration Law” 83 According to the article, the National Medical Products Administration organized a post-marketing evaluation of phenolphthalein tablets and phenolphthalein lozenges. The evaluation concluded that phenolphthalein tablets and phenolphthalein lozenges had serious adverse reactions, and the risk of use in China was greater than the benefit. It was decided to stop phenolphthalein tablets from today. For the production, sales and use of Hephenolphthalein lozenges in China, the drug registration certificate (drug approval number) will be cancelled. The phenolphthalein tablets and phenolphthalein lozenges that have been on the market are recalled by the manufacturer, and the recalled products are supervised and destroyed by the drug regulatory authority where the company is located.